Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERLEADA vs ANDROID 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erleada (apalutamide) is an androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR, preventing AR nuclear translocation, DNA binding, and transcription of AR target genes. It also inhibits AR-mediated tumor growth and reduces prostate-specific antigen (PSA) levels.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Treatment of non-metastatic castration-resistant prostate cancer (nm CRPC),Treatment of metastatic castration-sensitive prostate cancer (m CSPC)
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
240 mg orally once daily on an empty stomach, taken at least 1 hour before or 2 hours after a meal. Swallow tablets whole.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Terminal elimination half-life is approximately 20 hours (range 16-24 hours) at steady state, supporting once-daily dosing.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Primarily metabolized by CYP2C8 and CYP3A4 to form active metabolites (N-desmethyl apalutamide). It is also a strong inducer of CYP3A4 and CYP2C9, and has moderate effects on CYP2C19 and UGTs.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Fecal (87.4%) as unchanged drug and metabolites; renal (2.4%) as unchanged drug.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Highly protein bound (97%) primarily to albumin and α1-acid glycoprotein (AAG).
98% bound to sex hormone-binding globulin (SHBG) and albumin.
Apparent volume of distribution (Vd/F) is approximately 157 L (about 2.2 L/kg for a 70 kg adult), indicating extensive extravascular distribution.
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Oral bioavailability is not determined due to lack of intravenous formulation; after oral administration, absorption is rapid with Tmax of 2 hours under fasting conditions; food increases Cmax by 2- to 4-fold and AUC by 2-fold.
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; use with caution.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate (Child-Pugh B): reduce dose to 120 mg once daily. Severe (Child-Pugh C): not recommended.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Safety and efficacy not established in pediatric patients; no specific pediatric dosing available.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
No specific dose adjustment required based on age alone; monitor for adverse effects (e.g., falls, hypertension) more frequently in elderly patients.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
No boxed warning.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
Seizure: Increased risk, especially in patients with predisposing factors; discontinue if seizure occurs.,Falls and fractures: Increased incidence in clinical trials; assess fall and fracture risk.,Cardiovascular effects: Hypertension, especially in patients with pre-existing cardiovascular disease.,Thyroid dysfunction: Monitor thyroid function tests periodically.,Hypercholesterolemia: Monitor lipid profile and manage accordingly.,Hypersensitivity reactions: Including angioedema; discontinue if severe.
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Pregnancy: Apalutamide can cause fetal harm and is contraindicated in pregnant women.,Severe hypersensitivity to apalutamide or any component of the formulation.
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
Grapefruit and grapefruit juice may increase apalutamide concentrations; avoid consumption. No other food interactions known.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
Risk Category X. ERLEADA (apalutamide) can cause fetal harm when administered to a pregnant woman. Nonclinical studies have demonstrated teratogenicity, including skeletal abnormalities and reduced fetal weight, at exposures below the recommended human dose. As male patients exposed to ERLEADA may father a child, a pregnancy test should be conducted for female partners of reproductive potential prior to initiating therapy. Advise male patients to use effective contraception during treatment and for 3 months after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
No data available on the presence of apalutamide in human milk, its effects on the breastfed infant, or its effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from ERLEADA, advise women not to breastfeed during treatment and for at least 3 months after the last dose. The milk-to-plasma ratio is unknown.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
ERLEADA is contraindicated in pregnancy. No dose adjustment is recommended for non-pregnant patients; however, due to the risk of fetal harm, use is not recommended during pregnancy. Pharmacokinetic changes of apalutamide specifically during pregnancy have not been studied, and no dose adjustments are recommended as the drug is not used in pregnant women.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
ERLEADA (apalutamide) requires concomitant use with a Gn RH analog or bilateral orchiectomy. Monitor for hypertension, hypothyroidism, and hypercholesterolemia. Falls and fractures are increased; assess fracture risk. Use with caution in patients at risk for seizures, as clinical seizures occurred in 0.2% of patients. Dose adjustment for CYP3A4 substrates with narrow therapeutic index.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Take ERLEADA once daily at the same time each day, with or without food. Swallow tablets whole; do not crush or chew.,Use effective contraception during treatment and for 3 months after last dose. ERLEADA can cause fetal harm.,Report any signs of infection, falls, fractures, or seizures immediately. Risk of falls and fractures is increased.,Blood pressure, thyroid function, and cholesterol levels will be monitored regularly. Report symptoms of hypothyroidism like fatigue or cold intolerance.,Avoid grapefruit, grapefruit juice, or products containing grapefruit while on ERLEADA.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERLEADA vs ANDROID 5, answered by our medical review team.
ERLEADA is a Androgen Receptor Inhibitor Antineoplastic that works by Erleada (apalutamide) is an androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR, preventing AR nuclear translocation, DNA binding, and transcription of AR target genes. It also inhibits AR-mediated tumor growth and reduces prostate-specific antigen (PSA) levels.. ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERLEADA and ANDROID 5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERLEADA is: 240 mg orally once daily on an empty stomach, taken at least 1 hour before or 2 hours after a meal. Swallow tablets whole.. The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERLEADA and ANDROID 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERLEADA is classified as Category C. Risk Category X. ERLEADA (apalutamide) can cause fetal harm when administered to a pregnant woman. Nonclinical studies have demonstrated teratogenicity, including skeletal abnormal. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.